NovoCure (NVCR) Current Deferred Revenue (2015 - 2019)

NovoCure has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $19.6 million for Q4 2019.

• Current Deferred Revenue for Q4 2019 came in at $19.6 million, up 4.32% year-over-year; the trailing twelve-month figure through Dec 2019 was $19.6 million (up 4.32% YoY), and the FY2019 annual result was $19.6 million, up 4.32% from the prior year.
• Current Deferred Revenue came in at $19.6 million for Q4 2019 at NovoCure, up from $18.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $19.6 million in Q4 2019 to a low of $52000.0 in Q4 2015.
• The 5-year median for Current Deferred Revenue is $5.0 million (2017), against an average of $9.1 million.
• Across the five-year window, Current Deferred Revenue surged 4259.62% in 2016 and climbed 4.32% in 2019, its largest moves.
• NovoCure's Current Deferred Revenue stood at $52000.0 in 2015, then soared by 4259.62% to $2.3 million in 2016, then surged by 118.75% to $5.0 million in 2017, then soared by 278.48% to $18.8 million in 2018, then advanced by 4.32% to $19.6 million in 2019.
• The last three Current Deferred Revenue figures came in at $19.6 million (Q4 2019), $18.8 million (Q4 2018), and $5.0 million (Q4 2017), per Business Quant data.